Literature DB >> 2459256

Production of monoclonal antibodies against human erythropoietin and their use in the purification of human urinary erythropoietin.

H Miyazaki1, H Kozutsumi, T Kato, S Hoshi, S Tamura, M Kubota, T Suzuki.   

Abstract

Several murine monoclonal antibodies (MAbs) specific for human erythropoietin (HuEpo) were produced by hybridomas obtained from the fusion of murine myeloma cells, P3X63-Ag.8-653, with the splenocytes of mice immunized with recombinant human Epo (rHuEpo). Based on epitope analysis by a competitive binding assay, these MAbs could be classified into at least three groups: (1) 1E10, (2) 1H7, (3) 2D6, 3D6 and 3D8. In a sandwich enzyme-linked immunosorbent assay (ELISA), using these MAbs as the solid-phase antibodies, MAb-bound HuEpo was detected with rabbit anti-HuEpo sera. Some combinations of two different classes of MAbs, such as 1H7 and 3D8, were found to capture much more HuEpo than each MAb used individually. Urinary HuEpo (U-HuEpo) was highly purified from the urine of patients with severe aplastic anemia with about 50% final recovery using an immunoaffinity column on which a mixture of 1H7 and 3D8 was immobilized. The purified U-HuEpo had a specific activity of 77,340 U/mg in a radioimmunoassay (RIA) and of 76,673 U/mg using an in vivo bioassay.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459256     DOI: 10.1016/0022-1759(88)90340-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  2 in total

1.  Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium.

Authors:  H Kimata; A Yoshida; C Ishioka; S Masuda; R Sasaki; H Mikawa
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

2.  Effect of recombinant human erythropoietin on human IgE production in vitro.

Authors:  H Kimata; A Yoshida; C Ishioka; H Mikawa
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.